S
epsis is a clinical syndrome defined by a systemic response to infection. The interaction of various mediators affects the condition of septic patients. Other than the inflammatory cytokines, such as tumor necrosis factor (TNF)-␣ or interleukin (IL)-1␤, high-mobility group box-1 protein (HMGB1), nuclear architectural chromatin-binding protein, has recently been shown to be a lethal late-phase mediator of sepsis (1) .
HMGB1 is secreted by activated monocytes or macrophages (2) , and is released by necrotic or damaged cells (3) . Extracellular HMGB1 mediates cell-to-cell signaling and triggers activation of proinflammatory pathways (4) . HMGB1 released in the extracellular space provokes the production of inflammatory cytokines (2) and, subsequently, activated cytokines can activate the further release of HMGB1 into the extracellular space (5) . Elevated concentrations of HMGB1 are correlated with the severity of sepsis (2, 6) . HMGB1 was originally identified as a DNA-binding protein, but once released into the extracellular space HMGB1 can bind to receptors for advanced glycation end products. This may trigger the activation of serious inflammation (7) and resulting in severe tissue damage (2) (3) (4) 8) . Suppression of the production of inflammatory cytokines and the blockade of HMGB1 may improve the clinical outcomes of septic patients.
Thrombomodulin (TM) is an endothelial anticoagulant cofactor that plays an important role in the regulation of intravascular coagulation (9) . TM accelerates the thrombin-catalyzed activation of protein C to produce activated protein C, resulting in the inhibition of monocyte and macrophage activation (10, 11) . As a result, TM suppresses the production of inflammatory cytokines, such as TNF-␣ and IL-1␤, via the action of activated protein C (11). In addition, recent studies have shown that TM binds to HMGB1 and is capable of preventing its interaction with receptors for advanced glycation end products (12) .
We hypothesize that administration of TM improves survival in sepsis by inhib-iting the production of inflammatory cytokines and the lethal effects of HMGB1. Recombinant human soluble TM (ART-123) homologous to the extracellular domains of TM. This study investigated the effect of recombinant human soluble thrombomodulin (ART-123) administration on levels of inflammatory cytokines, plasma HMGB1 concentrations, and curative effect in vivo in rats with lipopolysaccharide (LPS)-induced endotoxemia.
MATERIALS AND METHODS
Materials. LPS (Escherichia coli, O26: B6) was purchased from Sigma-Aldrich Chemical (St Louis, MO). ART-123 was used for experimental studies, which is provided by Asahi Kasei Pharma (Tokyo, Japan).
Animals. All experiments were performed on pathogen-free male Sprague-Dawley rats weighing 250 -300 g (Kyudou, Saga, Japan). The guiding principles for the care and use of animals approved by the University of Occupational and Environmental Health were followed in these experiments. All animals were housed with free access to food and water ad libitum.
In vivo Endotoxemia Model. Animals were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg). To evaluate the therapeutic effect of ART-123 in experimental endotoxemia, the animals were randomly divided into groups, as indicated in Figure 1 . LPS (4 mg/kg) was administered as a bolus injection into the tail vein (LPS group). ART-123 (1 mg/kg) was administered as a bolus injection into the tail vein 30 minutes before or 4 hour after LPS injection (ART-123 pretreated/treated group). As a control, an equal volume of physiologic saline was administered instead of LPS and ART-123 (control group). We decided to use ART-123 at a dosage of 1 mg/kg, as described elsewhere (13) . Survival was monitored for up to 2 weeks (n ϭ 10 per group).
Experimental Protocol. Blood samples were collected from pentobarbital-anesthetized rats and were anticoagulated with 3.15% sodium citrate. Anticoagulated blood samples with sodium citrate were centrifuged immediately for 10 minutes at 3000g, and the plasma supernatant was separated. The degree of liver dysfunction was evaluated through the measurement of plasma aspartate aminotransferase and alanine aminotransferase (SRL, Kitakyushu, Japan). Commercial enzymelinked immunosorbent assay kits were used for measurement of inflammatory cytokines (Biosource, Camarillo, CA), thrombin-antithrombin III complex (TAT) (Dade Behring, Tokyo, Japan), and HMGB1 (Shino-TEST, Kanazawa, Japan).
Immunohistochemical Staining of the Liver. Rat liver tissue specimens were embedded in paraffin and sectioned into 2 m slices. Immunohistochemical staining for HMGB1 was performed using a rabbit polyclonal antibody (Shino-TEST). After blocking the endogenous peroxidase activity, sections were preincubated with 10% normal goat serum for 20 minutes. The sections were incubated with a 1:500 dilution of the primary antibody HMGB-1 overnight at 4°C. Then the sections were incubated with EnVision ϩ reagent (EnVision ϩ System, DAKO, Carpinteria, CA) for 30 minutes. 3,3-diaminobenzidine was used as the substrate, and the sections were counterstained with Mayer's hematoxylin and mounted. The immunostaining of rat macrophages with ED2 (AbD Serotec, Oxford, UK) was performed according to the methods described previously (14) .
Statistical Analysis. The data are presented as the mean Ϯ SEM. The data were analyzed using one-way analysis of variance and unpaired Student's t test for single comparisons. A p value of Ͻ0.05 was considered to be statistically significant.
RESULTS

Effect of ART-123 on the Plasma Levels of TNF-␣ and IL-1␤.
The plasma levels of TNF-␣ and IL-1␤ increased following injection of LPS, peaking at 1 and 3 hours after injection of LPS, respectively (Fig. 2) . These increases were less prominent in rats treated with ART-123 than in those receiving LPS alone. Plasma levels of TNF-␣ and IL-1␤ did not increase in the control group at any time point assayed (data not shown).
Effect of ART-123 on the Plasma Levels of Thrombin-Antithrombin III Complex. The thrombin-antithrombin III complex level in the LPS group significantly increased in comparison with the control group at 6 hours after LPS injection, and ART-123 suppressed this increase (Fig. 3) .
Effect of ART-123 on the Plasma Levels of HMGB1. Plasma levels of HMGB1 increased over time following injection of LPS. ART-123 administration markedly decreased the plasma levels of HMGB1, even with delayed treatment of ART-123 (Fig. 4) . Plasma levels of HMGB1 did not increase in the control group at any time point assayed (data not shown). 
Effect of ART-123 on the Plasma
Concentrations of Liver Enzymes. Injection of LPS induced a significant increase in the plasma concentrations of these liver enzymes at 12 hours after injection of LPS; ART-123 suppressed this increase in both ART-123 treatment groups (Fig. 5) .
Immunohistochemical and Histopathologic Examination of the Rat Liver. The LPS administration increased the migration of hepatic macrophages in the liver tissue, which was inhibited by treatment with ART-123 (Fig. 6A) . In the LPS group, strong and extensive immunostaining for HMGB1 was observed in the hepatic macrophages and hepatocyte nuclei. This positive immunostaining for HMGB1 was less pronounced among ART-123 pretreated rats than in the LPS group (Fig. 6B) (Fig. 7) . There was extensive hepatocellular necrosis and collapse of nuclei observed in the LPS group. This change was significantly increased at 9 hours after injection of LPS. Both ART-123 treatment groups showed markedly reduced necrosis of the hepatic cells and the collapse of the nuclei in comparison with the LPS group.
Survival Rate. Injection of LPS induced death in 50% of the rats in the LPS group within 2 weeks. In contrast, a total of 90% of the rats in the both ART-123 treatment groups survived 2 weeks after injection of LPS. A Kaplan-Meier analysis revealed a significantly shorter time-todeath among the LPS group in comparison with both ART-123 treatment groups (Fig. 8 ).
DISCUSSION
Our study produced two important findings. First, elevation of the plasma HMGB1 levels was suggested to be a prognostic indicator for survival in experimental endotoxemia. Second, our study showed that ART-123 decreases the plasma HMGB1 levels and protects against its lethal effects, even with delayed treatment.
HMGB1 is actively secreted from macrophages and monocytes, which are acti- vated by inflammatory cytokines (2), and it is also passively released from necrotic cells (3, (15) (16) (17) (18) . In our model, the plasma levels of HMGB1 showed a statistically significant increase at 6 hours after LPS injection. At that time, the levels of both TNF-␣ and IL-1␤ were already increased, and the migration of hepatic macrophages were observed. In addition, there were no microscopic observations of liver cell damage and no change in the plasma concentrations of liver enzymes at 6 hours after LPS injection. Consequently, it is probably correct to consider that this increase of plasma HMGB1 consisted mainly of the active secretion from activated macrophages and monocytes. Thereafter, the liver tissue showed cellular necrosis and the collapse of nuclei and the plasma concentrations of aspartate aminotransferase and alanine aminotransferase both significantly increased over time in conjunction with a rapid increase in the plasma HMGB1 levels. Therefore, this rise of HMGB1 seems to be the result of the accumulation of HMGB1 passively released from necrotic cells. The mortality rate was markedly increased as well as rapidly increase the level of plasma HMGB1 simultaneously. These results suggest that the elevation of the plasma HMGB1 levels may be a prognostic indicator for survival in experimental endotoxemia.
It has been reported that inflammatory cytokines, such as TNF-␣ and IL-1␤, contribute to the pathogenesis of sepsis, and the inhibition of these cytokines is thought to be important in the prevention of sepsis (19, 20) . These cytokines also decrease the anticoagulant activity of sinusoidal endothelial cells compounding microthrombus formation (21, 22) and liver dysfunction. Therefore, therapies directed against inflammatory mediators (23, 24) and anticoagulant therapies (25, 26) , such as the conventional treatment of sepsis, have been devised and dramatic effects are observed in experimental model of rats. However, the successful results from animal models cannot necessarily be translated into the clinical setting for humans (27) (28) (29) (30) (31) (32) . The sequestration of HMGB1 seems to be necessary in addition to suppressing the production of inflammatory cytokines for successful mortality reduction. Many anti-inflammatory or anticoagulant therapies suppress the production of inflammatory cytokines, thereby inhibiting the production of HMGB1. However, these therapies cannot neutralize HMGB1 that has already been secreted into the extracellular space. In clinical sepsis, the active secretion and the passive release of HMGB1 are already initiated and the protein is accumulated in systemic circulation. Therefore, the direct inhibition of existing HMGB1 is necessary on clinical diagnosis. This may account for the limited efficacy of these therapies in clinical trials, although the therapeutic effects of these therapies have been observed in pretreated animal models.
Conversely, TM forms a reversible complex with thrombin to convert protein C into activated protein C (33-39), thereby inhibiting the active secretion of HMGB1 by suppressing the activation of macrophages and monocytes (11) . In addition, recent studies have shown that TM binds and sequesters HMGB1 directly at the level of D1 of TM (12) . We observed the administration of ART-123 to significantly attenuate the systemic accumulation of HMGB1, thus mitigating its lethal effects even with delayed treatment. It seems that the therapeutic window of TM is wider than for other traditional therapies directed against inflammatory cytokines, and the results may support the possibility of TM as an effective clinical therapy for humans.
TM also plays an important role in the attenuation of thrombin formation associated with the properties of activated protein C (40) , which reflects the strong negative feedback control of the thrombin generation (41) . In this study, we demonstrated that ART-123 suppressed thrombin-antithrombin III complex formation. During sepsis, HMGB1 and thrombin present in the circulation would propagate inflammatory and coagulatory responses to remote organs (7) . A recent study suggested that the lethal activity of HMGB1 may be dependent on thrombin (42) .
Our results raise a question concerning the anti-HMGB1 mechanism of TM. ART-123 administration showed an obviously decreased reaction of immunostaining in the hepatocyte nuclei for HMGB1 in comparison with the LPS group. It was, thus, suggested that TM also has an effect on the intranuclear expression of HMGB1. Previous reports have already demonstrated the anti-HMGB1 property of TM in the extracellular environment (12) . However, the property of TM in the intranuclear expression of HMGB1 has not yet been examined, and requires further study.
In conclusion, TM probably has an antiinflammatory activity, which partly protects against the lethal effects of HMGB1. Furthermore, TM also inhibits the generation of thrombin. TM may, therefore, play an important role in the treatment of sepsis. These results must be confirmed by multicenter randomized controlled studies of the efficacy of TM for the treatment of sepsis; to date, only one report regarding the efficacy of TM for the treatment of disseminated intravascular coagulation has previously been published (43) .
CONCLUSION
The blockade of HMGB1 markedly reduces liver dysfunction and mortality, and therefore the elevation of the plasma HMGB1 levels is thought to be a prognostic indicator for survival in endotoxemia. Our study demonstrated that ART-123 inhibits the production of inflammatory cytokines and decreases the plasma HMGB1 levels in experimental endotoxemia, even with delayed treatment of ART-123. These findings suggest that the use of TM may therefore be a beneficial treatment for septic patients.
